Authors
Latest:
Daily Antituberculosis Therapy Superior for Pulmonary TB in PLWHA daily, 6-month ATT regimen in HIV-positive patients with TB receiving concomitant ART proved superior to an intermittent regimen in terms of efficacy and prevention of ARR.
Latest:
Early Chemotherapy for Ovarian Cancer Relapse Based on Serial CA-125 Monitoring does Not Improve Overall Survival or Quality of LifeEarly chemotherapy for relapsed ovarian cancer based on serial monitoring of CA-125 levels failed to improve overall survival or quality of life compared with delayed therapy according to clinical signs and symptoms of relapse in a large European trial.
Latest:
Heart failure and sudden death in patients with tachycardia-induced cardiomyopathy and recurrent tachycardiaThe effects of recurrent tachycardia after resolution of cardiomyopathy have not been thoroughly assessed. We evaluated and followed 24 patients with tachycardia-induced cardiomyopathy for more than 12 years. Our observations showed that patients with tachycardia-induced cardiomyopathy may be at long-term risk for sudden death. Surreptitious cardiomyopathy due to occult ultrastructural changes may persist. It has yet to be determined whether rapid and aggressive rate control would prevent structural damage to risk of sudden cardiac death.
Latest:
ADHD Drugs and AddictionA community pharmacist shares his insights and opinions on concerns over the risks involved with ADHD medications for children.
Latest:
Hypertension in the elderlyMore important than the choice of pharmaceutical agent in the treatment of elderly hypertensive patients is the achievement of goal blood pressure. Low-dose diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and calcium channel blockers are equally effective in reducing cardiovascular end points. Most patients will require 2 or more drugs to achieve target blood pressure, and physicians should feel comfortable prescribing 3 to 4 agents to a significant proportion of patients.
Latest:
Sex-related differences in treatment and outcome in patients with ACSThe AMIS (Acute Myocardial Infarction in Switzerland) Plus prospective cohort study compared treatment and in-hospital outcomes between men and women with acute coronary syndrome (N = 26,452) admitted to Swiss hospitals between 1997 and 2007. The study reached several important conclusions: women had different baseline characteristics than men at admission, were treated with different drug regimens, and were significantly less likely to undergo percutaneous coronary intervention. After adjusting for these differences, researchers found no significant difference in the rates of in-hospital mortality between men and women, except for women aged 51 to 60 years, who were more likely to die in-hospital.
Latest:
Vodou Baby--the Birth of a SurgeonA Haitian nurse offered advice: "Keep your textbook nearby".
Latest:
What is the Most Effective Treatment Strategy for Patients with Secondary Progressive Multiple Sclerosis?Experts examine conflicting evidence regarding the continuation of disease-modifying therapy in patients with secondary progressive multiple sclerosis.
Latest:
2018-2019 Flu Vaccine Recommendations from ACIPNew recommendations from the CDC's Advisory Committee on Immunization Practices reveal that health care providers have the intranasally-administered live attenuated influenza vaccine (LAIV) among their arsenal of available vaccines for the 2018-2019 flu season.
Latest:
Medication-Free Strategies Can Prevent Coronary Heart DiseaseDrug therapy is recognized as an effective way to lower lipids and control hypertension, and for its effect on reducing the incidence of myocardial infarction. However, the impact of personal habits, such as eating, drinking, smoking, and exercise, on the incidence of coronary heart disease without reliance on prescription medications and their potential side effects may be less well established.
Latest:
National Strategy to Reduce Prescription Drug AbusePsychiatrist Steven Roy Daviss, MD provides a detailed review of the elements in the National Drug Control Strategy.
Latest:
Early Momentum for a Genomic Approach to Sickle Cell Disease TherapyIn a late-breaking presentation at ASGCT 2022, investigators shared preclinical results of a gene-editing strategy that seeks to reactivate developmentally silenced fetal hemoglobin (HbF, α2γ2) in order to replace defective sickle hemoglobin (HbS, α2βS2).
Latest:
Interoperability and Standards: The Effect on Patient CareAs clinicians, we are increasingly accustomed to using EMRs in the hospital, as well as practice management and billing systems in the office.
Latest:
BRAF Mutation Emerging as Prognostic in KRAS Wild-Type CRC PatientsColorectal cancer patients who had wild-type (normal) KRAS gene status, but mutations in the BRAF, had a poor prognosis in spite of treatment with cetuximab.
Latest:
Get Connected with Online Physician ConsultationsHow does today’s connected, "always on" world translate to your medical practice?
